Meningococcal vaccine groups A C Y W-135 conjugate - JN-International Medical Corporation

Drug Profile

Meningococcal vaccine groups A C Y W-135 conjugate - JN-International Medical Corporation

Alternative Names: NmVac-4DT; NmVac4-A/C/Y/W-135-DT; NmVac4-ACYW135 DT

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator JN-International Medical Corporation
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Meningococcal-group-A-infections(Prevention) in Ivory Coast (IM, Injection)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Meningococcal-group-C-infections(Prevention) in Ivory Coast (IM, Injection)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Meningococcal-group-W-135-infections(Prevention) in Ivory Coast (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top